Printer Friendly

Chronic Urticaria / Hives Therapeutic Pipeline H2 2014 Review Research Report.

DALLAS, December 17, 2014 /PRNewswire/ --

RnRMarketResearch.com adds "Chronic Urticaria Or Hives - Pipeline Review, H2 2014" therapeutic market research report of 67 pages with latest updates, data and information to its online business intelligence library.

The Chronic Urticaria Or Hives - Pipeline Review, H2 2014 therapeutic industry research report provides an overview of the Chronic Urticaria or Hives therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Urticaria or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of Chronic Urticaria Or Hives Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Chronic Urticaria Or Hives pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=250221.

Companies discussed in this research include AstraZeneca PLC, Biofrontera AG, Bristol-Myers Squibb Company, ELORAC, Inc., F. Hoffmann-La Roche Ltd., FAES Farma SA, Genentech, Inc. and Merck & Co., Inc.

Reasons to buy Chronic Urticaria or Hives Pipeline Review, H2 2014 research report:

* Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

* Develop strategic initiatives by understanding the focus areas of leading companies

* Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives

* Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

* Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics

* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Explore more reports on the Dermatology therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics.

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252

Tel: +1-888-391-5441 sales@rnrmarketresearch.com
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Dec 17, 2014
Words:914
Previous Article:Enterprise Ends Europcar's Licence to Operate National and Alamo Brands.
Next Article:Abengoa's Ain Beni Mathar Hybrid Solar-Gas Plant Awarded by the African Development Bank.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters